Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study.

J Am Heart Assoc · 2025 · PMC12229191 · PMID 40417813

Europe PMC DOI

hedged sentences

0.0840

closest p · 1.7× alpha

0.0840

boldest claim

The sentences

showed a trendP =0.084so close (0.05 < p ≤ 0.1)

In the remote zone, the empagliflozin group showed a trend toward increased total NO levels compared with the control‐MI ( P =0.084) and empagliflozin+sacubitril/valsartan groups ( P =0.059).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Although LVEF increased the most in the empagliflozin+sacubitril/valsartan group compared with the control‐MI and empagliflozingroups, this change did not reach statistical significance (Table 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.